Combined effect of compressing fresh concrete and curing regime on bonding performance of high strength repair mortar.

High strength concrete (HSC) is highly appropriate for the retrofitting and rehabilitation of reinforced concrete structures due to its low permeability and high bonding strength. However, its low workability and sensitivity to curing conditions pose significant challenges for its implementation in such projects. This study introduces a novel technique to overcome the workability barrier of HSC while enhancing its bonding strength under various curing conditions.

Utilization and integration of microalgae consortium in treating undiluted anaerobic digestate animal effluent to produce animal feed, bio-oil, and biogas.

Anaerobic digestate animal effluent (ADAE) contains high N and P nutrients which need to be treated. In this study, an integrated process was proposed using a microalgae consortium of Chlorella and Scenedesmus. The system was designed for 71 m/d (medium-sized) and 355 m/d (large-sized) animals of ADAE.

Studying the Impact of European Union Regulatory Interventions for Minimising Risks From Medicines: Lessons Learnt and Recommendations.

Purpose: The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) launched a strategy to examine the public health impact of major regulatory interventions aimed at minimising risks of medicinal products. We conducted a lessons learnt analysis of impact studies completed between 2015 and 2023.

Methods: We surveyed PRAC Sponsors and (Co-)Rapporteurs involved in the evaluation of 12 impact studies (10 commissioned by EMA and 2 conducted collaboratively by Member States) to explore how these support regulatory decision-making.

The STAR Compass to Guide Future Pharmacovigilance Based on a 10-Year Review of the Strengthened EU System.

This article reflects on the 2010 pharmacovigilance legislation of the European Union (EU). Its legislative aim of better patient and public health protection through new responsibilities for pharmaceutical companies and regulatory bodies is considered to have been achieved and is well supported by the good pharmacovigilance practices 'EU-GVP'. For future progress, we set out a vision for high-quality pharmacovigilance in a world of ongoing medical, technological and social changes.

Medicines for an aging population: The EMA perspective and policies.

The European Medicines Agency adopted their Geriatric Medicines Strategy more than a decade ago. The strategy aims at elucidating the evidence basis for marketing authorization of new medicines which will be used in the older population, and at ensuring the appropriate communication of findings to the patient and healthcare provider. During the past decade new tools and data sources have emerged to support the strategy goals, and their use should be considered.